Cyprotex PLC ("Cyprotex" or "the Company" or "the Group")
Cyprotex (LSE:CRX), the drug discovery technology and information company, notes yesterday's fall in the share price and is unaware of any reason for this share price movement. The Company re-iterates that its current trading is in line with market expectations following its trading update of 20 November 2009.
The Company expects to release a trading update towards the end of January 2010, in respect of calendar year ended 31 December 2009.
For further information:
Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0) 1625 505 100
Noble & Company
John Llewellyn-Lloyd
Tel: +44 (0) 20 7763 2200
john.llewellyn-lloyd@noblegp.com
Financial Dynamics
Ben Brewerton / Ben Atwell / John Dineen
Tel: +44 (0) 20 7831 3113
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com